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NEW HORIZONS
Cre-ativity in the Liver: Transgenic Approaches to
Targeting Hepatic Nonparenchymal Cells
Stephen N. Greenhalgh, Kylie P. Conroy, and Neil C. Henderson
Rapid evolution in transgenic (Tg) mouse technology now permits cell-specific and tem-
poral control of fluorescent cell-labeling and gene inactivation. Here, we discuss the
principal strategies that have been utilized to target, label, and manipulate hepatic non-
parenchymal cells, with emphasis on the utility of constitutive and inducible Cre-lox
systems. We summarize key findings of studies employing Tg technology to target
hepatic stellate cells, myofibroblasts, liver sinusoidal endothelial cells, and macrophages
to illustrate the power of these approaches in identifying cell-specific molecular mecha-
nisms critical to the pathophysiology of liver disease. Increasing adoption of Tg techni-
ques will help to answer fundamental questions regarding the pathogenesis of hepatic
diseases and provide the mechanistic rationale to allow identification of novel drug
targets, ultimately translating into effective therapies for patients with liver disease.
(HEPATOLOGY 2015;61:2091-2099)
T
ransgenic (Tg) mouse technology has evolved
rapidly since the turn of the century, facilitat-
ing major advances in our understanding of
hepatic pathobiology in murine models of human liver
disease. Initial Tg manipulations were restricted to
global gene knockout, greatly limiting the study of
genes with vital functions during development owing
to embryonic or perinatal lethality. These limitations
have largely been circumvented through development
of techniques, such as Cre-lox, that permit targeted
genetic manipulation, allowing both spatial and tem-
poral control of gene expression in mice. Conditional
deletion of targeted genomic DNA sequences has
become a standard approach, facilitating both interrog-
ation of cell-specific gene function and detailed study
of cell ontogeny through fate mapping. Within the
liver, these techniques have revolutionized our ability
to interrogate the roles of specific genes and cell line-
ages in a broad range of hepatic disease processes.
Here, we discuss how this burgeoning field is being
harnessed to explore the myriad roles of hepatic non-
parenchymal cells (NPCs) in the pathophysiology of
liver disease.
Tg Systems
Cre-lox
Developed in the 1980s, the Cre-lox system is cur-
rently one of the most widely used techniques for
genetic manipulation in mice.1 The bacteriophage P1
cre (cyclization recombinase) gene catalyzes DNA
recombination between pairs of loxP (locus of X-over
in P1) sites. Spatial expression of Cre is achieved using
cell-specific cre promoters, whereas inducible systems
can restrict expression temporally. The location and
orientation of the loxP sites dictate whether Cre ini-
tiates deletion, inversion, or translocation of the
“floxed” (flanked by loxP) locus. Typically, loxP sites
are inserted a short distance apart on the same chro-
mosome, in the same orientation, resulting in excision
of the floxed segment and preventing successful pro-
duction of a functional gene product (Fig. 1A).
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Alternatively, a floxed STOP codon may be inserted,
whereby transcription of the downstream sequence,
commonly a fluorescent reporter construct, only pro-
ceeds following Cre-mediated excision (Fig. 1A). Thus,
Cre-lox permits intrinsic cellular labeling through cell-
specific and, if required, temporally restricted, fluores-
cent protein expression. These manipulations require
at least two Tg modifications, inserting Cre and loxP
sites respectively, and are achieved by interbreeding
strains carrying a single transgene. Therefore, this per-
mits essentially any combination of Cre driver and
floxed allele.
“Conditional” Cre Expression
Cell-specific Cre expression is achieved using a cell-
specific promoter element. In constitutive systems, pro-
moter activation leads directly to Cre expression and
recombination. However, constitutive systems do not
permit a defined cohort of cells to be labeled at a spe-
cific point in time (temporal Cre expression), which
negates their use in true fate-mapping experiments.
Furthermore, constitutive Cre-driven ablation of devel-
opmentally important genes, even if cell specific, has
the potential for embryonic lethality. As such, use of
inducible Cre-lox systems, in which an exogenous
stimulus is required to permit Cre-mediated recombi-
nation, has increased in recent years. This temporal
regulation of Cre can be mediated through systems
including Cre fusion proteins or the tetracycline (Tet)
system.
The commonly used tamoxifen-inducible system
employs a Cre fusion protein, CreERT2, containing a
mutated ligand-binding domain of the estrogen recep-
tor.2 This construct prevents Cre from entering the
Fig. 1. Schematic diagram of cell-specific Cre recombinase-induced gene inactivation and fluorescent reporter expression systems. (A) Cell-
specific expression of Cre recombinase results in excision of loxP-flanked sequences leading to gene inactivation or fluorescent reporter expres-
sion. (B) Spatiotemporal regulation of Cre activity: tamoxifen (TAM) administration permits entry of the Cre-ERT2 complex into the nucleus, allow-
ing excision of loxP-flanked sequences.
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nucleus and driving recombination until exogenously
administered tamoxifen binds to the fusion protein
(Fig. 1B). Two principle versions of the Tet-inducible
system exist: Tet-ON and Tet-OFF.2 Both rely on the
insertion of TetO operator sequences upstream from a
gene of interest and the separate incorporation of a tet-
racycline activator (TA) protein (tTA or rtTA) into the
genome. Tet administration, usually as doxycycline,
then either promotes (Tet-ON) or prevents (Tet-OFF)
expression of the gene of interest. The Tet system’s
main strength is the potential for reversible gene
(in)activation. It can also be combined with Cre-lox,
by either placing cre downstream of the TetO sequen-
ces or using Cre to switch on rtTA or tTA
transcription.
Both tamoxifen and Tet systems require careful dose
titration to maximize recombination efficiency while
minimizing unwanted side effects. Low-level back-
ground recombination and poor recombination effi-
ciency can be problematic. Tamoxifen may persist in
the liver for 1-4 weeks after injection, and higher doses
can cause nonspecific recombination.3 Either may con-
found accurate fate mapping by labeling additional cell
types. As such, experimental design must be carefully
considered, with use of appropriate controls crucial to
confirm that observed effects are the result of the
intended Cre-lox manipulation.
Viral Vector-Mediated Regulation of Cre
Expression
Viral vectors can also be employed to enable trans-
gene expression in specific cell types in mice. Recombi-
nant adeno-associated viruses are nonpathogenic
helper-dependent parvoviruses with viral encoding pro-
teins replaced by a gene or construct of interest, such
as cre. This system has been utilized for elegant fate-
mapping studies in the liver using a hepatocyte-
targeted, adeno-associated virus containing Cre.4,5
Flp-FRT
Analogous to Cre-lox, but of fungal rather than viral
origin, Flp-FRT is an alternative system in which tar-
geted genetic manipulation occurs through flippase
(Flp)-mediated recombination of inserted flippase rec-
ognition target (FRT) sites.2 The recombination effi-
ciency and thermostability of Flp have lagged behind
that of Cre, although adoption of Flp variants, such as
FLPe and FLPo, have greatly increased its utility.2,6
The system is already commonly used to remove anti-
biotic resistance genes during generation of Tg mouse
strains. Although not yet widely adopted in the liver,
use of Flp-FRTmay well expand in coming years. Spe-
cifically, combination with Cre-lox allows independent
or sequential gene manipulation, which may greatly
aid modeling of cancer development in mice.7
Reporter Systems
Cre-lox is an extremely powerful tool to label cells
permanently and heritably, as required for fate-
mapping studies. The ROSA26 locus is frequently
used for the generation of “Rosa26R” reporter strains
owing to its robust and ubiquitous expression.8 Com-
mon fluorescent reporter constructs (Fig. 2) include
ZsGreen, TdTomato, membrane-targeted tdTomato
membrane-targeted enhanced green fluorescent protein
(mTmG), variants of enhanced green fluorescent pro-
tein (eGFP), and multicolor reporters, such as Con-
fetti.9 Fluorescent constructs are constantly evolving to
maximize fluorescence and fidelity and incorporate
additional refinements, such as localization tags to
allow cytosolic, membrane, and nuclear targeting.9
Fluorescent reporters also permit cell sorting without
additional antibody staining and are of particular use
when isolating cell types present at low frequency.
Potential Cre Pitfalls
Off-target effects of Cre (“Cre toxicity”) have been
reported and may occur through a variety of mecha-
nisms, including insertion site activation or silencing,
undocumented gene expression patterns, incomplete
incorporation of driver construct regulatory elements,
transgene silencing, and germline expression.10 Unin-
tended Cre expression (“leakiness”) in nontargeted lin-
eages or at inappropriate times may confound the
conclusions of both gene deletion and fate-mapping
experiments. Therefore, it is essential that the recombi-
nation efficiency (sensitivity) and expression pattern
(specificity) for each Cre strain is carefully character-
ized and appropriate controls are selected.
Targeting Hepatic NPCs
Defining the role of NPCs in liver disease is vital to
understand the pathobiology driving disease progres-
sion, particularly given the common pathway of
inflammation to fibrosis to organ failure shared by
most chronic liver diseases. The Cre drivers currently
utilized to target hepatic NPCs are listed in Table 1,
and the principal cell targets are illustrated in Fig. 3.
Harnessing Tg mouse technology in models of human
liver disease should allow for the identification of novel
therapeutic targets. Given that there is now strong evi-
dence that liver fibrosis is reversible,11 determining the
means by which hepatic stellate cells (HSCs),
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myofibroblasts, macrophages, and liver sinusoidal
endothelial cells (LSECs) contribute to progression
and regression of liver fibrosis, as well as hepatic regen-
eration, is of great importance.
Targeting HSCs and Myofibroblasts
Myofibroblasts are the principal profibrogenic cells
in the liver, and there is now substantial in vivo evi-
dence that HSCs, liver-specific pericytes residing in the
space of Disse, are their major precursor.12 Thus,
HSCs and liver myofibroblasts are of profound interest
in the search for potent antifibrotic treatments.
Lecithin-Retinol Acyltransferase
This HSC-targeting strategy capitalizes on their spe-
cialized role in retinoid storage, employing a Tg mouse
in which Cre expression is driven by lecithin-retinol
acyltransferase (Lrat), an enzyme with a key role in
HSC lipid droplet formation.12 In two fluorescent
reporter systems, Lrat-Cre labeled 99% of HSCs
(defined by vitamin A fluorescence on flow cytometry).
Confocal microscopy revealed strong colocalization
with the HSC markers, desmin and platelet-derived
growth factor receptor beta (PDGFRb). Furthermore,
Lrat protein expression was not identified in any other
Fig. 2. Labeling of hepatic NPCs
with fluorescent reporters. (A and B)
Lrat-Cre-driven ZsGreen labeling of
qHSCs and aHSCs in whole livers from
untreated (A) and CCl4-treated (B)
mice. Adapted by permission from Mac-
millan Publishers Ltd: Nat Commun,12
VC 2013. (C and D) Pdgfrb-Cre-driven
membranous GFP labeling (green) of
qHSCs and aHSCs in Pdgfrb-Cre;mTmG
mice following olive oil (control, C) or
chronic CCl4 (D) administration.
Adapted by permission from Macmillan
Publishers Ltd: Nat Med,13 VC 2013. (E)
Tamoxifen-induced Cdh5-PAC-CreERT2-
driven TdTomato (red) labeling of
LSECs. Nuclei (blue), a-SMA1 cells
(green). Adapted from Supplementary
Information to a previous work,29 by
permission from the authors. (F) LysM-
Cre-driven membranous GFP labeling
(green) of macrophages in uninjured
liver of LysM-Cre;mTmG mice (K.P.C.
and N.C.H., unpublished data).
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hepatic cell type. Only rare labeling of vascular smooth
muscle cells (VSMCs) was observed (<1 per 200
HSCs). Thus, this strategy targets HSCs efficiently
and with high specificity.
In models of toxic, cholestatic, and fatty liver dis-
ease, Lrat-Cre-driven reporter expression showed that
82%-96% of hepatic myofibroblasts, in part identified
by concomitant expression of a collagen (Col)-GFP
transgene (in which GFP is expressed under control of
the Col-a1 (I) promoter/enhancer), derive from HSCs.
However, HSCs did not function as epithelial progeni-
tors. Combining Lrat-Cre with a Cre-inducible diph-
theria toxin receptor resulted in marked HSC
depletion and reduction in alpha-smooth muscle actin
(a-SMA) and profibrogenic gene expression after CCl4
administration, again underlining the central role of
HSCs in matrix deposition during liver fibrogenesis.
Platelet-Derived Growth Factor Receptor Beta
Pdgfrb-Cre mice represent an alternative strategy to
target HSCs and myofibroblasts.13 These mice express
Cre under control of a Pdgfrb gene fragment and drive
efficient recombination in both quiescent HSCs
(qHSCs) and activated myofibroblasts with a high
degree of specificity.13 A Pdgfrb-BAC-eGFP reporter
confirmed PDGFRb expression by qHSCs and offers
an additional genetic strategy for fluorescent labeling
of HSCs. The Pdgfrb-Cre strategy identified a key role
for myofibroblast av integrins in regulating fibrosis in
several solid organs, including liver, lung, and kidney.
Selective depletion of av integrins from HSCs pro-
tected mice from CCl4-induced hepatic fibrosis, and
av-null HSCs had reduced ability to activate latent
transforming growth factor beta. These findings were
further validated using a small-molecule inhibitor to
target av integrins, which ameliorated fibrosis in both
liver and lung.
Glial Fibrillary Acidic Protein
A number of studies have used glial fibrillary acidic
protein (GFAP)-Cre to target HSCs constitutively or
inducibly.14-17 However, it has been suggested that
GFAP-Cre does not target HSCs with high specificity.
Using a GFAP-Cre mouse (in which the human
GFAP promoter controls Cre expression) crossed to a
GFP reporter, GFAP, Cre-recombinase, and GFP
reporter protein were detected in both HSCs and
ductular cells of the biliary system.14 GFAP ductular
expression was also confirmed in human and rat liver.
Subsequently, GFAP-Cre reporters have demonstrated
labeling of bile ducts and cytokeratin 19–expressing
Table 1. Cre Drivers That May Be Used
to Target Hepatic NPCs
Hepatic NPC Type Cre Driver
Cre
System
Other Relevant Cells
That May Be Targeted References
HSC/myofibroblast Lrat c VSMC (12)
Pdgfrb c VSMC (13)
GFAP c, i Ductular cell,
cholangiocyte
(12,14-17)
Myofibroblast a-SMA i VSMC (17,19)
Cola1(I) c (16)
Cola2(I) c, i (16)
Vimentin i HSC, VSMC,
portal fibroblast
(25)
LSEC Cdh5 i (29)
KC/macrophage LysM c Granulocyte, DC (34,36-38)
Csf1r i Granulocyte, DC (42,43)
Abbreviations: c, constitutive; i, inducible.
Fig. 3. Tg approaches to
targeting NPCs in the liver.
qHSC: Lrat and Pdgfrb; Mac
(macrophage): Csfr1 and
LysM; LSEC: Cdh5; myofibro-
blast: a-SMA, Col-a1(I), Col-
a2(I), Lrat, Pdgfrb, and
vimentin.
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cholangiocytes, rather than desmin1 HSCs or
collagen-producing myofibroblasts.12 Thus, it appears
that GFAP-Cre does not target HSCs exclusively and
its overall utility in murine studies of liver disease has
still to be fully clarified.
a-SMA
Myofibroblasts are classically identified by a-SMA
expression.18 An inducible Cre linked to a-SMA (a-
SMA-Cre-ERT2) has been employed to target hepatic
myofibroblasts.17,19 High recombination rates (57%-
81%) were achieved when using a-SMA-Cre-ERT2 to
abrogate smoothened expression from a-SMA1 liver
cells and loss of smoothened disrupted Hedgehog sig-
naling and reduced fibrosis after bile duct ligation
(BDL). Myofibroblast accumulation and hepatocyte
proliferation were also inhibited following BDL or
partial hepatectomy (PH). Interestingly, when a-
SMA-Cre-ERT2 mice were crossed with a yellow fluo-
rescent protein (YFP) reporter, YFP expression was
reported in 8%-34% of hepatocytes following PH or
BDL. This finding raised the possibility that the a-
SMA1 myofibroblast population includes hepatocyte
precursors, contrary to current dogma and subse-
quently challenged by alternative fate-mapping
approaches.12,20,21
Collagen
Activated HSCs (aHSCs) are the major source of
collagen within the liver,12,22,23 and several Tg mouse
strains exist in which collagen-expressing cells have
been targeted.16 In a Col-GFP Tg mouse, following 2
months of liver injury with CCl4, 92.6% of all GFP
1
cells in the nonparenchymal fraction were a-SMA1,
demonstrating good specificity for myofibroblasts. Fur-
ther characterization of these GFP1 cells suggested
that HSCs (vitamin A1 and desmin1) are the major
source (92%) of myofibroblasts in this model of liver
injury. Col-GFP mice have also enabled phenotypic
analysis of the GFP1 myofibroblast population follow-
ing BDL.24 In contrast to CCl4 injury, vitamin A
2
cells initially (days 5 and 17 post-BDL) formed the
majority of myofibroblasts following cholestatic liver
injury. Additional characterization defined a Thy11,
elastin1, and desmin2 population that was suggested
to comprise portal fibroblasts.
Col-a1(I) and Col-a2(I) form the triple helix of col-
lagen type I. In mice containing either the constitutive
Col-a1(I)-Cre or Col-a2(I)-Cre transgenes, each
crossed with a YFP reporter and following 2 months
of CCl4, >92% of a-SMA
1 cells and >94% of
desmin1 cells expressed YFP reporter, providing evi-
dence that recombination occurs with high efficiency
in myofibroblasts/aHSCs.16 Furthermore, when a
tamoxifen-inducible Col-a2(I)-CreER was crossed with
a mTmG reporter, 35% of desmin1 HSCs were
labeled by 7 daily doses of tamoxifen administered
after 7 weeks of CCl4.
These three targeting-reporter strategies revealed
that hepatic myofibroblasts can revert to an inactive
HSC phenotype during regression of CCl4-induced
fibrosis.16 In the Col-a2(I)-CreER targeting strategy,
14% of desmin1 HSCs were GFP1 1 month after
recovery, almost half the number labeled at peak fibro-
sis. Similar results were observed in a model of
alcohol-induced liver fibrosis. Notably, Col-GFP mice
receiving a second course of CCl4, after complete
recovery from the first, developed more-severe fibrosis
than previously untreated littermate controls receiving
CCl4 for the first time.
Vimentin
Vimentin is a cytoskeletal filament protein strongly
expressed in mesenchymal cells, particularly myofibro-
blasts. A tamoxifen-inducible Cre under control of the
vimentin promoter has been employed to track activa-
tion and reversion of HSCs and myofibroblasts follow-
ing cessation of liver injury.25 Minimal reporter
expression was detected in uninjured liver, suggesting
that this strategy is unsuitable for targeting qHSCs.
Following chronic CCl4 injury, 25% of HSCs were
labeled, with all labeled cells desmin1.
Targeting LSECs
LSECs comprise a unique endothelial subpopulation
lining hepatic sinusoids. They differ both morphologi-
cally and functionally from the endothelia of other
organs, with numerous fenestrae, no basement mem-
brane, and a diverse range of roles.26 Although there
are currently no LSEC-specific Cre drivers, a general
endothelial-targeted Cre driver has recently been suc-
cessfully employed to target LSECs.
Vascular Endothelial Cadherin
Vascular endothelial cadherin is a cell-cell glycopro-
tein coded for by the cdh5 gene and is the major cad-
herin expressed by LSECs.27 Its key functions are
endothelial cohesion and intercellular junction organi-
zation. A tamoxifen-inducible Cdh5-PAC-CreERT2
strain, initially utilized in studies of angiogenesis,28
successfully targets LSECs.29 Following tamoxifen,
TdTomato reporter expression was widespread in
endothelial cells, but did not label desmin1,
PDGFRb1, or a-SMA1 cells. The Cdh5-PAC-
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CreERT2 strategy was then employed to knock down
LSEC expression of C-X-C chemokine receptor
(CXCR)4, CXCR7, or fibroblast growth factor recep-
tor 1 (FGFR1). LSEC-specific Cxcr7 knockdown sig-
nificantly reduced hepatocyte proliferation after acute
liver injury (single-dose CCl4) and, following chronic
injury (BDL or chronic CCl4), impaired regeneration
and promoted fibrosis. Conversely, loss of CXCR4 or
FGFR1 in LSECs limited the profibrotic changes
occurring after BDL, demonstrating that FGFR1-
mediated CXCR4 up-regulation can counterbalance
the LSEC proregenerative response and promote fibro-
sis. Thus, LSECs, through CXCR7 and CXCR4, play
a key role in liver injury and repair.
Targeting Macrophages in the Liver
Liver injury stimulates both activation of Kupffer
cells (KCs), the liver-resident macrophages, and infil-
tration of circulating macrophages. Macrophage subpo-
pulations are critical for both fibrogenesis and its
resolution,30 and it is therefore essential to dissect the
underlying mechanisms regulating these divergent
responses to injury. Currently, the greatest challenges
in Tg targeting of liver macrophages are unresolved,
namely, distinguishing macrophages from other cells of
the myeloid lineage and the ability to target liver-
resident macrophages separately from recruited macro-
phage populations.31 Despite these limitations, the Tg
approaches outlined below have proved useful tools for
targeting myeloid cell populations within the liver.
M Lysozyme
In mice, M lysozome (LysM) is specifically
expressed in myeloid cells and up-regulated following
macrophage activation.32 In the LysM-Cre mouse,
recombination rates of 83%-95% were achieved in
peritoneal macrophages positive for the classical mac-
rophage marker, F4/80.33 However, recombination was
also observed in up to 99% of thioglycollate-elicited
peritoneal neutrophils and a minority of dendritic cells
(DCs). Recently, it was shown that variable LysM
expression by macrophage subsets can result in differ-
ential recombination, with immature macrophages
showing less recombination than mature, tissue-
resident macrophages.34 This work also elegantly dem-
onstrated the differing roles of macrophage subpopula-
tions during schistosomiasis-induced hepatic fibrosis.
LysM-Cre, combined with a GFP reporter, has also
been employed to track loss of KC membrane integrity
following Ad5 adenovirus infection,35 and in further
gene deletion studies.36-38 Using LysM-Cre to knock
down peroxisome proliferator-activator receptor
gamma (PPAR-c) was shown to reduce macrophage
expression of both PPAR-c isoforms to <25% of base-
line and, in both acute and chronic CCl4-induced liver
injury, these mice demonstrated increased liver injury
and fibrosis.38
Colony-Stimulating Factor 1 Receptor
The c-fms gene encodes colony-stimulating factor 1
receptor (CSF1R), expression of which is restricted to
cells of the myeloid lineage (and placental tropho-
blasts).39 The “MacGreen” knock-in mouse combines
the proximal promoter and first intron of the c-fms
gene with the coding sequence for eGFP, labeling mac-
rophages throughout the mouse.39 In liver, eGFP1 cell
location and morphology was similar to that of F4/
801 cells, although simultaneous costaining was not
performed in the initial characterization. Although
transgene expression initially appeared restricted to
monocytes and macrophages, expression in granulo-
cytes40 and DCs41 was subsequently confirmed.
The Csf1r promoter has also been employed to tar-
get a tamoxifen-inducible Cre (Csf1r-Mer-iCre-Mer)
to myeloid cells, and its initial characterization demon-
strated a reduction in peripheral blood monocyte vas-
cular endothelial growth factor A expression to 16% of
baseline.42 No reduction in expression was observed in
other circulating immune cells, including granulocytes.
A key advantage of the Csf1r-Mer-iCre-Mer mouse is
that it permits both cell-specific and temporal control
of Cre-mediated recombination. This has enabled
pulse labeling and lineage tracing of yolk sac macro-
phages in developing embryos, distinguishing them
from macrophages derived from hematopoietic stem
cells later in gestation.43 Although a relatively small
proportion (0.3%-6.3%) of tissue macrophages were
labeled by this strategy, a similar approach could allow
macrophage targeting at specific time points during
liver injury and regeneration and may therefore be use-
ful in fate-mapping studies of KCs.
Challenges and Future Directions
Tg mouse technology continues to evolve rapidly,
advancing our understanding of the cellular and
molecular mechanisms regulating hepatic injury,
wound healing, and regeneration. Novel Cre drivers,
with improved specificity and efficiency, and increasing
adoption of inducible Cre strategies will enable high-
fidelity interrogation of the precise role of individual
cell lineages during the development and resolution of
liver disease. Fluorescent reporter systems also offer
exciting potential for further exploitation; in addition
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to fluorescent cell sorting, combining fluorescent
reporters with techniques such as laser capture micro-
dissection, single-cell real-time polymerase chain reac-
tion and even single-cell RNA sequencing, offers
enormous opportunities.
However, it is critically important that, as Tg tech-
nology advances, a rigorous approach to its utilization
is applied in order to ensure that robust, high-quality
data are generated. Excellent catalogs of available Tg
strains are already in existence, but it is essential that
researchers developing new mouse strains, or utilizing
existing strains in novel applications, characterize
them fully with regard to targeting efficiency and
specificity.
Through an increasingly finessed approach to
genetic manipulation, we are gaining an ever more
detailed picture of the cellular and subcellular processes
that regulate hepatic pathology. Harnessing Tg tech-
nology in the liver will help identify rational antifi-
brotic and proregenerative targets, facilitating efficient
translation of scientific discoveries into potent thera-
pies for patients.
References
1. Nagy A. Cre recombinase: the universal reagent for genome tailoring.
Genesis 2000;26:99-109.
2. Branda CS, Dymecki SM. Talking about a revolution: the impact of
site-specific recombinases on genetic analyses in mice. Dev Cell 2004;6:
7-28.
3. Tarlow BD, Finegold MJ, Grompe M. Clonal tracing of Sox91 liver
progenitors in mouse oval cell injury. HEPATOLOGY 2014;60:278-289.
4. Malato Y, Naqvi S, Sch€urmann N, Ng R, Wang B, Zape J, et al. Fate
tracing of mature hepatocytes in mouse liver homeostasis and regenera-
tion. J Clin Invest 2011;121:4850-4860.
5. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S,
et al. Cholangiocarcinomas can originate from hepatocytes in mice.
J Clin Invest 2012;122:2911-2915.
6. Wu Y, Wang C, Sun H, LeRoith D, Yakar S. High-efficient FLPo dele-
ter mice in C57BL/6J background. PLoS One 2009;4:e8054.
7. Sch€onhuber N, Seidler B, Schuck K, Veltkamp C, Schachtler C,
Zukowska M, et al. A next-generation dual-recombinase system for
time- and host-specific targeting of pancreatic cancer. Nat Med 2014;
20:1340-1347.
8. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter
strain. Nat Genet 1999;21:70-71.
9. Abe T, Fujimori T. Reporter mouse lines for fluorescence imaging. Dev
Growth Differ 2013;55:390-405.
10. Heffner CS, Pratt CH, Babiuk RP, Sharma Y, Rockwood SF, Donahue
LR, et al. Supporting conditional mouse mutagenesis with a compre-
hensive cre characterization resource. Nat Commun 2012;3:1218.
11. Ellis EL, Mann DA. Clinical evidence for the regression of liver fibro-
sis. J Hepatol 2012;56:1171-1180.
12. Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al.
Fate tracing reveals hepatic stellate cells as dominant contributors to liver
fibrosis independent of its aetiology. Nat Commun 2013;4:2823.
13. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez
JD, McCarty JH, et al. Targeting of av integrin identifies a core molec-
ular pathway that regulates fibrosis in several organs. Nat Med 2013;
19:1617-1624.
14. Yang L, Jung Y, Omenetti A, Witek RP, Choi S, Vandongen HM,
et al. Fate-mapping evidence that hepatic stellate cells are epithelial pro-
genitors in adult mouse livers. Stem Cells 2008;26:2104-2113.
15. Scholten D, €Osterreicher CH, Scholten A, Iwaisako K, Gu G, Brenner
DA, et al. Genetic labeling does not detect epithelial-to-mesenchymal
transition of cholangiocytes in liver fibrosis in mice. Gastroenterology
2010;139:987-998.
16. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, et al.
Myofibroblasts revert to an inactive phenotype during regression of
liver fibrosis. Proc Natl Acad Sci U S A 2012;109:9448-9453.
17. Michelotti GA, Xie G, Swiderska M, Choi SS, Karaca G, Kr€uger L,
et al. Smoothened is a master regulator of adult liver repair. J Clin
Invest 2013;123:2380-2394.
18. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmoulie`re A, Varga
J, et al. Recent developments in myofibroblast biology: paradigms for
connective tissue remodeling. Am J Pathol 2012;180:1340-1355.
19. Swiderska-Syn M, Syn WK, Xie G, Kruger L, Machado MV, Karaca
G, et al. Myofibroblastic cells function as progenitors to regenerate
murine livers after partial hepatectomy. Gut 2014;63:1333-1344.
20. Schaub JR, Malato Y, Gormond C, Willenbring H. Evidence against a
stem cell origin of new hepatocytes in a common mouse model of
chronic liver injury. Cell Rep 2014;8:933-939.
21. Yanger K, Knigin D, Zong Y, Maggs L, Gu G, Akiyama H, et al.
Adult hepatocytes are generated by self-duplication rather than stem
cell differentiation. Cell Stem Cell 2014;15:340-349.
22. de Leeuw AM, Mccarthy SP, Geerts A, Knook DL. Purified rat liver
fat-storing cells in culture divide and contain collagen. HEPATOLOGY
1984;4:392-403.
23. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the
principal collagen-producing cells of normal rat liver. Proc Natl Acad
Sci U S A 1985;82:8681-8685.
24. Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ,
et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl
Acad Sci U S A 2014;111:E3297-E305.
25. Troeger JS, Mederacke I, Gwak GY, Dapito DH, Mu X, Hsu CC,
et al. Deactivation of hepatic stellate cells during liver fibrosis resolu-
tion in mice. Gastroenterology 2012;143:1073-1083.e22.
26. Elvevold K, Smedsrød B, Martinez I. The liver sinusoidal endothelial
cell: a cell type of controversial and confusing identity. Am J Physiol
Gastrointest Liver Physiol 2008;294:G391-G400.
27. Geraud C, Evdokimov K, Straub BK, Peitsch WK, Demory A,
D€orflinger Y, et al. Unique cell type-specific junctional complexes in
vascular endothelium of human and rat liver sinusoids. PLoS One
2012;7:e34206.
28. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML,
Sakakibara A, et al. Ephrin-B2 controls VEGF-induced angiogenesis
and lymphangiogenesis. Nature 2010;465:483-486.
29. Ding B-S, Cao Z, Lis R, Nolan DJ, Guo P, Simons M, et al. Diver-
gent angiocrine signals from vascular niche balance liver regeneration
and fibrosis. Nature 2014;505:97-102.
30. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori
S, et al. Selective depletion of macrophages reveals distinct, opposing roles
during liver injury and repair. J Clin Invest 2005;115:56-65.
31. Abram CL, Roberge GL, Hu Y, Lowell CA. Comparative analysis of
the efficiency and specificity of myeloid-Cre deleting strains using
ROSA-EYFP reporter mice. J Immunol Methods 2014;408:89-100.
32. Keshav S, Chung P, Milon G, Gordon S. Lysozyme is an inducible
marker of macrophage activation in murine tissues as demonstrated by
in situ hybridization. J Exp Med 1991;174:1049-1058.
33. Clausen BE, Burkhardt C, Reith W, Renkawitz R, F€orster I. Condi-
tional gene targeting in macrophages and granulocytes using LysMcre
mice. Transgenic Res 1999;8:265-277.
34. Vannella KM, Barron L, Borthwick LA, Kindrachuk KN, Narasimhan
PB, Hart KM, et al. Incomplete deletion of IL-4Ra by LysM(Cre)
reveals distinct subsets of M2 macrophages controlling inflammation
and fibrosis in chronic schistosomiasis. PLoS Pathog 2014;10:
e1004372.
2098 GREENHALGH ET AL. HEPATOLOGY, June 2015
35. He JQ, Katschke KJ, Gribling P, Suto E, Lee WP, Diehl L, et al. CRIg
mediates early Kupffer cell responses to adenovirus. J Leukoc Biol
2013;93:301-306.
36. Moran-Salvador E, Lopez-Parra M, Garcıa-Alonso V, Titos E,
Martınez-Clemente M, Gonzalez-Periz A, et al. Role for PPARc in
obesity-induced hepatic steatosis as determined by hepatocyte- and
macrophage-specific conditional knockouts. FASEB J 2011;25:2538-
2550.
37. Sun Z, Miller RA, Patel RT, Chen J, Dhir R, Wang H, et al. Hepatic
Hdac3 promotes gluconeogenesis by repressing lipid synthesis and
sequestration. Nat Med 2012;18:934-942.
38. Moran-Salvador E, Titos E, Rius B, Gonzalez-Periz A, Garcıa-Alonso
V, Lopez-Vicario C, et al. Cell-specific PPARc deficiency establishes
anti-inflammatory and anti-fibrogenic properties for this nuclear
receptor in non-parenchymal liver cells. J Hepatol 2013;59:1045-
1053.
39. Sasmono RT, Oceandy D, Pollard JW, Tong W, Pavli P, Wainwright
BJ, et al. A macrophage colony-stimulating factor receptor-green fluo-
rescent protein transgene is expressed throughout the mononuclear
phagocyte system of the mouse. Blood 2003;101:1155-1163.
40. Sasmono RT, Ehrnsperger A, Cronau SL, Ravasi T, Kandane R, Hickey
MJ, et al. Mouse neutrophilic granulocytes express mRNA encoding
the macrophage colony-stimulating factor receptor (CSF-1R) as well as
many other macrophage-specific transcripts and can transdifferentiate
into macrophages in vitro in response to CSF-1. J Leukoc Biol 2007;
82:111-123.
41. MacDonald KPA, Rowe V, Bofinger HM, Thomas R, Sasmono T,
Hume DA, et al. The colony-stimulating factor 1 receptor is expressed
on dendritic cells during differentiation and regulates their expansion.
J Immunol 2005;175:1399-1405.
42. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al.
CCL2 recruits inflammatory monocytes to facilitate breast-tumour
metastasis. Nature 2011;475:222-225.
43. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard
N, Kierdorf K, et al. A lineage of myeloid cells independent of Myb
and hematopoietic stem cells. Science 2012;336:86-90.
Author names in bold designate shared co-first
authorship.
HEPATOLOGY, Vol. 61, No. 6, 2015 GREENHALGH ET AL. 2099
